Abeona Therapeutics Receives FDA Orphan Drug Designation For ABO-201 Juvenile Batten Disease Gene Therapy … – Clinical Leader
|
Abeona Therapeutics Receives FDA Orphan Drug Designation For ABO-201 Juvenile Batten Disease Gene Therapy …
Clinical Leader New York, NY and Cleveland, OH (GLOBE NEWSWIRE) – Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that … |
